Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company’s Lumipulse® G B•R•A•H•M•S PCT Assay for testing on its LUMIPULSE® G1200 immunoassay platform.
Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fujirebio” or “the Company”) announced today that it has entered into an agreement with US-based Janssen Pharmaceuticals, Inc. (hereinafter “Janssen”) to develop and commercialize an AMYLOID β 42/40 RATIO assay.
MedTest Holdings, the solution provider of choice offering integrated products and services for decentralized clinical diagnostic testing, today announced the debut of its new corporate name—MedTest Dx—at the upcoming 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting.
Brandwidth Solutions, LLC, a full-service marketing agency addressing science-based businesses, has been recognized as Best Specialist Life Science Marketing Agency 2018-Pennsylvania by AI Global Media.
SCIEX, a global leader in life science analytical technologies, advanced the accessibility of mass spectrometry in the clinical setting with new product introductions at AACC 2018. Today, SCIEX announced the launch of the new Topaz™ Prep Station, an automated sample preparation workstation that is ideal for labs managing high daily sample volumes, as well as the new automated Vitamin D 200A Assay Kit.
Hahn-Schickard enables complex clinical pictures to be diagnosed quickly and reliably directly at the point of care. The latest device generation allows the amplification of RNA and DNA by means of fast PCR in 20 - 25 minutes. This makes it possible, for example, to analyze a real patient sample fully automatically in 30 minutes. The device can also be used in the field of food analysis or environmental analysis.
NAMSA®, the world’s only Medical Research Organization (MRO) that accelerates medical device development through integrated laboratory testing, clinical research and regulatory consulting services, announced today the launch of its in vitro diagnostic (IVD) development business to provide global manufacturers a proven resource for expedited commercialization outcomes delivered via NAMSA’s “Uniquely IVD” regulatory, quality and clinical research services.
Neoteryx LLC today announced research recently published in the official peer-reviewed scientific journal of the European Federation of Clinical Chemistry and Laboratory Medicine, Clinical Chemistry and Laboratory Medicine. The research found that analysis of samples extracted from the company’s VAMS™ technology showed almost perfect agreement with results obtained from venous blood samples for HbA1c levels on a Tosoh G8 analyzer. The investigator-initiated clinical research study took place from June 2017 to January 2018 at Ghent University Hospital in Belgium. The study included 100 patients and was approved by the school’s Ethics Committee.
Neoteryx LLC, announced today the expansion of its patent-pending Mitra® Microsampling portfolio to now include a 30 µL tip size. The Mitra microsampling device which comes in a 10 µL, 20 µL and now 30 µL holds and transports a precise volume of blood typically collected from a finger prick.
Today, Neoteryx LLC, announced that it will supply its Volumetric Absorptive Microsampling (VAMS™) technology, in the form of the Mitra® microsampling device, to Alcala Labs of San Diego for a more efficacious, streamlined approach to monitor patients in recovery centers throughout the United States. By incorporating VAMS specimen collection and transportation technology into its CleanAssure™ clinical convenience kits and testing menu, Alcala Labs is the first to commercialize an offering to addiction recovery centers that analyzes a volumetrically accurate dried blood microsample collected from a simple finger prick to test for alcohol and opioids.
Magnefy offer an additional performance-driven solid phase for magnetic particle-based assays and isolations, including SPRI-based* total DNA isolation. (*Solid phase reversible immobilization, which features the isolation of high-purity nucleic acid in the presence of NaCl and PEG.)
Dynex Technologies announced today it has finalized a supply agreement with ZEUS Scientific (Branchburg, NJ) enabling ZEUS to sell Dynex instruments to the global clinical market.
The University of California San Diego and Spin, the dockless personal mobility company, are announcing the results of a bikeshare partnership pilot program which was created to provide more than 36,000 students, faculty and staff with an affordable, equitable and eco-friendly way to get around campus.
GenPrime Inc., a leading provider of digital technology platforms and lateral flow readers, has announced the development of a new handheld version of its FDA-cleared diagnostic test reader...
GenPrime Inc., a leading provider of digital technology platforms and lateral flow readers, has announced the development of a new high-throughput version of its FDA-cleared diagnostic test reader...